Volume 29, Number 7—July 2023
Dispatch
Detecting, Quantifying, and Isolating Monkeypox Virus in Suspected Cases, Spain
Table 1
Patient no. | Date | Age, y/sex | HIV serostatus | MSM/SP† | Sample type | Clinical features |
---|---|---|---|---|---|---|
1 | 2022 May 24 | 54/F | – | No | Lesion swab | Rash, fever |
2 | 2022 May 25 | 17/M | – | NA | Pharyngeal and oral swab | Acute pharyngitis |
3 | 2022 Jun 15 | 34/M | + | Yes | Lesion swab | Genital lesions |
4 | 2022 Jun 15 | 34/M | – | Yes | Lesion swab | Lesions, fever, adenopathies |
5 | 2022 Jun 15 | 49/M | + | Yes | Nasopharyngeal and lesion swab | Perioral lesions |
6‡ | 2022 Jun 17 | 39/M | + | Yes | Nasopharyngeal and lesion swab | Lip lesion, fever |
7 | 2022 Jun 18 and 21 | 45/M | + | Yes | Pharyngeal and lesion swabs | Perianal and pharyngeal discomfort, vesicular exanthema |
8 | 2022 Jun 20 | 25/F | – | No | Nasopharyngeal and lesion swab | Lesion |
9 | 2022 Jun 20 | 49/M | – | Yes | Lesion swab | Lesion |
10 | 2022 Jun 20 and 24 | 41/M | – | Yes | Nasopharyngeal and lesion swab | Febrile, pubic lesion |
11 | 2022 Jun 21 | 45/M | – | Yes | Lesion swab | Folliculitis in the context of scabies |
12 | 2022 Jun 24 | 43/M | – | Yes | Lesion swab | Odynophagia, folliculitis, genital lesion, fever |
13 | 2022 Jun 30 | 37/M | – | Yes | Lesion swab | Cutaneus and genital lesions, adenopathies |
14 | 2022 Jul 1 | 35/M | + | Yes | Nasopharyngeal, lesion swab, blood | Cutaneus and genital lesions, fever, adenopathies |
15 | 2022 Jul 1 | 29/M | + | Yes | Nasopharyngeal and lesion swab | Vesicular lesions on trunk, palms, and genitals, fever |
16 | 2022 Jul 2 | 35/M | + | No/Yes | Lesion swab | Odynophagia/cutaneus and genital lesions, fever, adenopathies |
17 | 2022 Jul 2 | 22/M | – | No/Yes | Lesion swab | Genital lesions |
18 | 2022 Jul 3 | 47/M | + | No | Lesion swab | Cutaneus and genital lesions |
19 | 2022 Jul 4 | 30/M | – | Yes | Nasopharyngeal and lesion swab | Lesions, fever |
20‡§ | 2022 Jul 4 | 26/M | – | Yes | Lesion and rectal swabs, blood | Lesions, fever |
21 | 2022 Jul 5 | 22/M | – | NA | Lesion swab | Itchy lesions |
22 | 2022 Jul 5 | 41/M | + | NA | Lesion swab | Lesions¶ |
23 | 2022 Jul 5 | 48/M | – | NA | Lesion swab | Lesions¶ |
24 | 2022 Jul 5 | 30/M | + | NA | Nasopharyngeal and lesion swab | Lesions¶ |
25 | 2022 Jul 6 | 26/M | – | NA | Nasopharyngeal and lesion swab | Lesions¶ |
26 | 2022 Jul 7 | 29/M | – | Yes | Lesion swab | Lesions¶ |
27 | 2022 Jul 8 | 28/M | – | NA | Lesion swab | Lesions¶ |
28 | 2022 Jul 8 | 60/M | – | NA | Pharyngeal and lesion swab | Lesions¶ |
29 | 2022 Jul 8 | 22/M | + | Yes | Pharyngeal and lesion swab, blood | Cutaneus and genital lesions |
30 | 2022 Jul 11 | 54/M | NA | NA | Lesion swab | Lesions¶ |
31 | 2022 Jul 11 | 47/M | – | Yes | Pharyngeal and lesion swab | Lesions, adenopathies |
32 | 2022 Jul 12 | 30/M | NA | NA | Lesion swab | Lesions¶ |
33 | 2022 Jul 12 | 32/F | NA | NA | Lesion swab | Lesions¶ |
34 | 2022 Jul 12 | 34/F | – | No | Pharyngeal and lesion swab | Necrotic lesions on forehead |
35 | 2022 Jul 13 | 19/F | NA | NA | Pharyngeal and lesion swab, blood | Umbilical lesions |
36 | 2022 Jul 13 | 56/M | NA | NA | Pharyngeal and lesion swab | Lesions¶ |
37 | 2022 Jul 13 | 21/M | – | No | Lesion swab | Lesions¶ |
38 | 2022 Jul 13 | 19/F | – | No | Lesion swab | Lesions¶ |
39 | 2022 Jul 14 | 34/F | – | No | Pharyngeal and lesion swab | Back rash in different stages of evolution |
40 | 2022 Jul 15 | 42/M | NA | NA | Lesion swab | Lesions¶ |
41 | 2022 Jul 15 | 30/M | + | Yes | Pharyngeal and lesion swab | Lesions, adenopathies |
*Gray shading indicates MPXV-infected patients. MPXV, monkeypox virus; MSM, men who have sex with men; NA, not available; SP, high-risk sexual practices; +, positive; –, negative. †No further information was available regarding attending clinicians’ criteria for high-risk sexual practices. ‡Inpatient. §Renal transplant patient. ¶No further clinical information available.
Page created: May 29, 2023
Page updated: June 20, 2023
Page reviewed: June 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.